MA43348A - Conjugués de protéines - Google Patents

Conjugués de protéines

Info

Publication number
MA43348A
MA43348A MA43348A MA43348A MA43348A MA 43348 A MA43348 A MA 43348A MA 43348 A MA43348 A MA 43348A MA 43348 A MA43348 A MA 43348A MA 43348 A MA43348 A MA 43348A
Authority
MA
Morocco
Prior art keywords
protein conjugates
conjugates
proteins
polypeptides
compounds include
Prior art date
Application number
MA43348A
Other languages
English (en)
Inventor
Emiliano Cló
Mikael Kofod-Hansen
Nils Langeland Ohansen
Henrik Sune Ramírez-Andersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA43348A publication Critical patent/MA43348A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des conjugués de protéines et en particulier des conjugués de plus de deux protéines ou polypeptides. Les composés comprennent un fragment de liaison trivalent qui permet une production efficace de produits souhaités.
MA43348A 2015-10-01 2016-09-30 Conjugués de protéines MA43348A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15187937 2015-10-01

Publications (1)

Publication Number Publication Date
MA43348A true MA43348A (fr) 2018-08-08

Family

ID=54252136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43348A MA43348A (fr) 2015-10-01 2016-09-30 Conjugués de protéines

Country Status (7)

Country Link
US (1) US11292825B2 (fr)
EP (1) EP3355931B1 (fr)
JP (1) JP6949832B2 (fr)
CN (1) CN108136043B (fr)
ES (1) ES2985999T3 (fr)
MA (1) MA43348A (fr)
WO (1) WO2017055582A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (fr) 2015-10-01 2024-06-26 Novo Nordisk A/S Conjugués de protéines
EP3532497B1 (fr) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Régions charnières d'immunoglobuline modifiées pour réduire l'hémagglutination
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
MA68842B1 (fr) * 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
WO2021115497A2 (fr) * 2020-12-08 2021-06-17 和铂医药(上海)有限责任公司 Conjugué protéine-médicament et procédé de conjugaison spécifique à un site
CN113024669B (zh) * 2021-03-12 2022-06-14 北京华科泰生物技术股份有限公司 含氨基或羧基基团物质标记的rbp抗体、人rbp免疫层析检测试剂盒及其制备方法
CN115819611B (zh) * 2021-12-30 2024-05-28 君合盟生物制药(杭州)有限公司 生长激素融合蛋白及其制备方法和用途
CN115845032B (zh) * 2022-10-28 2026-02-06 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途
WO2025184552A2 (fr) * 2024-03-01 2025-09-04 The Scripps Research Institute Conjugués peptidiques doubles gip/glp-1 et procédés d'utilisation
JP2026031900A (ja) * 2024-07-24 2026-02-25 イーライ リリー アンド カンパニー Ｆｃ－アシル化ポリペプチドコンジュゲート

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE257197C (fr)
DE286509C (fr)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3628333B2 (ja) 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
WO1998022577A1 (fr) 1996-11-15 1998-05-28 Maria Grazia Masucci Proteines de fusion a demi-vie allongee
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
AU782496B2 (en) 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
WO2002055532A2 (fr) 2001-01-11 2002-07-18 Maxygen Aps Molecules d'hormone de croissance ameliorees
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
EP1444262A2 (fr) 2001-11-12 2004-08-11 University of Wales College of Medicine Variations de l'hormone de croissance chez les humains et leurs utilisations
GB2389115B (en) 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
WO2004029207A2 (fr) 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
EP2368579A1 (fr) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Conjugaison au moyen de transglutaminase de peptides
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CN103172747A (zh) 2005-01-25 2013-06-26 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
US20090036353A1 (en) 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
KR20070108180A (ko) 2005-02-16 2007-11-08 노보 노르디스크 에이/에스 구조적으로 잘 정의된 분지형 중합체와 콘쥬게이트된인슐린분비제 유도체
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
WO2006116260A2 (fr) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101330931B (zh) 2005-12-12 2012-09-05 创新生物科学有限公司 制备缀合物
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2863222A1 (fr) 2006-03-06 2015-04-22 Amunix Operating Inc. Polymères recombinants non structurés et leurs utilisations
EP2054437A2 (fr) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Protéines de fusion d'albumine et d'insuline
ES2410886T3 (es) 2006-10-26 2013-07-03 Janssen Biotech, Inc. Métodos para la adaptación al ser humano de anticuerpos monoclonales
WO2008049711A1 (fr) 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
CA2687377C (fr) 2007-05-30 2013-05-14 Genexine Co., Ltd. Proteines de fusion d'immunoglobuline
EP2666787B1 (fr) 2007-05-31 2022-02-09 Genmab A/S ANTICORPS IgG4 STABLES
WO2009015345A1 (fr) 2007-07-25 2009-01-29 Amgen Inc. Compositions pharmaceutiques comprenant des protéines de fusion fc
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
WO2009027369A1 (fr) 2007-08-24 2009-03-05 Novo Nordisk A/S Procédé pour modifier de manière sélective une protéine
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
PT2310412T (pt) 2008-06-20 2018-05-28 Novartis Ag Imunoglobulinas com agregação reduzida
WO2010001196A1 (fr) 2008-07-02 2010-01-07 Koninklijke Philips Electronics N.V. Configuration de ressort en v et ensembles de fixation d'extrémité pour celle-ci destinés à être utilisés dans un appareil de soins d'hygiène corporelle
EP2300501B1 (fr) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles
ES2612252T3 (es) 2008-11-10 2017-05-16 Novo Nordisk A/S Cepa de E. coli BL21 que carece de un complejo génico funcional de los genes capsulares del grupo II
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
BR112012010252A2 (pt) 2009-10-29 2016-12-06 Janssen Biotech Inc variantes de glicosilação de anticorpo
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AU2011254564B2 (en) 2010-05-21 2014-03-27 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US20130143815A1 (en) 2010-07-22 2013-06-06 Novo Nordisk Health Care Ag Growth hormone conjugates
EP2694528A1 (fr) 2011-04-05 2014-02-12 Martin-Protean, LLC Isolement de peptides contenant de la cystéine
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2013170272A2 (fr) 2012-05-11 2013-11-14 Alexander Krantz Marquage spécifique d'un site et administration ciblée de protéines pour le traitement d'un cancer
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN105764530B (zh) 2013-11-26 2019-09-13 诺华股份有限公司 用于对酮修饰的多肽类进行肟缀合的方法
WO2015081073A2 (fr) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions et procédés pour moduler une réponse immunitaire
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
US11279771B2 (en) 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
CN107810202A (zh) 2015-02-17 2018-03-16 韩美药品株式会社 长效胰岛素或胰岛素类似物复合物
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
RU2698727C9 (ru) 2015-08-14 2022-03-30 Рс Биотекнолоджиз, Инк. Ковалентные линкеры в конъюгатах антитело-лекарственное средство, способы их получения и применение
EP3355931B1 (fr) 2015-10-01 2024-06-26 Novo Nordisk A/S Conjugués de protéines
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
WO2020074544A1 (fr) 2018-10-10 2020-04-16 Novo Nordisk A/S Conjugués insuline-fc à extension oligomère et leur utilisation médicale

Also Published As

Publication number Publication date
US20180282387A1 (en) 2018-10-04
JP2018535195A (ja) 2018-11-29
EP3355931C0 (fr) 2024-06-26
CN108136043B (zh) 2022-09-06
US11292825B2 (en) 2022-04-05
CN108136043A (zh) 2018-06-08
JP6949832B2 (ja) 2021-10-13
EP3355931B1 (fr) 2024-06-26
EP3355931A1 (fr) 2018-08-08
ES2985999T3 (es) 2024-11-08
WO2017055582A1 (fr) 2017-04-06

Similar Documents

Publication Publication Date Title
MA43348A (fr) Conjugués de protéines
IL272064A (en) Binding proteins 1
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12017502180A1 (en) Tau-binding antibodies
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
MA50942A (fr) Protéines de liaison à l'adn modifiées
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
SG11202104297XA (en) Novel rationally designed protein compositions
PH12018502361B1 (en) Gdf15 fusion proteins and uses thereof
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EP3443014A4 (fr) Constructions multi-spécifiques de liaison à l'antigène ciblant des agents immunothérapeutiques
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471B1 (fr) Compositions comprenant des souches bactériennes
MX2021003685A (es) Inhibicion dirigida del factor de crecimiento transformador b (tgfb).
TN2017000539A1 (en) Tau-binding antibodies
GB201917046D0 (en) Improved protein production
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
SI3731872T1 (sl) Postopek za zagotavljanje sestavka PEGiliranih beljakovin
GB201919294D0 (en) Antibodies or binding proteins
PT3806660T (pt) Barra proteica
EP3309169A4 (fr) Anticorps se liant spécifiquement à des peptides dérivés de la vimentine isolés ou fragment de liaison du peptide
PH12017502277A1 (en) Multi-specific binding proteins
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use